A comprehensive review on time-tested anticancer drug doxorubicin

Sritharan, Sruthi; Sivalingam, N

doi:10.1016/j.lfs.2021.119527

Cited by 242 publications

(177 citation statements)

References 112 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…MDR is the cellular mechanism by which patients' cancer cells develop resistance to unrelated chemotherapy drugs [142,143]. Doxorubicin (DOX) is one of the drugs commonly used in the treatment of many types of cancer, including breast, lung, ovarian, bladder, gastric, and thyroid cancer [144,145]. Propolis resulted in the inhibition of proliferation of DOXresistant lung cancer cells (A549) [146].…”

Section: The Use Of Propolis and Its Components In Cancer Therapymentioning

confidence: 99%

Anticancer Activity of Propolis and Its Compounds

2021

View full text Add to dashboard Cite

Propolis is a natural material that honey bees (Apis mellifera) produce from various botanical sources. The therapeutic activity of propolis, including antibacterial, antifungal, and anti-inflammatory effects, have been known since antiquity. Cancer is one of the major burdens of disease worldwide, therefore, numerous studies are being conducted to develop new chemotherapeutic agents and treatments for cancer. Propolis is a rich source of biologically active compounds, which affect numerous signaling pathways regulating crucial cellular processes. The results of the latest research show that propolis can inhibit proliferation, angiogenesis, and metastasis of cancer cells and stimulate apoptosis. Moreover, it may influence the tumor microenvironment and multidrug resistance of cancers. This review briefly summarizes the molecular mechanisms of anticancer activity of propolis and its compounds and highlights the potential benefits of propolis to reduce the side effects of chemotherapy and radiotherapy.

show abstract

Section: The Use Of Propolis and Its Components In Cancer Therapymentioning

confidence: 99%

Anticancer Activity of Propolis and Its Compounds

2021

View full text Add to dashboard Cite

show abstract

“…In this regard, glycomics studies on adriamycin-resistant AML cell lines have also reported the involvement of α-2,6 and α-2,8 sialylation on N -glycans in chemoresistance [ 27 , 28 ]. More precisely, by a stepwise addition of the chemotherapeutic adriamycin, which is widely used in the treatment of several solid tumors and acute leukemias [ 29 ], a multi drug resistance (MDR) phenotype was induced [ 27 ]. Aberrant sialylation identified in these resistant cells mediated a change in the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway accompanied by altered expression of P-glycoprotein and MDR-related protein 1, both of which are strongly associated with chemoresistance [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines

Blöchl

Wang

Madunić

et al. 2021

Cells

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is characterized by a dysregulated expansion of poorly differentiated myeloid cells. Although patients are usually treated effectively by chemotherapy, a high rate of relapsed or refractory disease poses a major hurdle in its treatment. Recently, several studies have proposed implications of protein glycosylation in the pathobiology of AML including chemoresistance. Accordingly, associations have been found between specific glycan epitopes and the outcome of the disease. To advance this poorly studied field, we performed an exploratory glycomics study characterizing 21 widely used AML cell lines. Exploiting the benefits of porous graphitized carbon chromatography coupled to tandem mass spectrometry (PGC nano-LC-MS2), we qualitatively and quantitatively profiled N- and O-linked glycans. AML cell lines exhibited distinct glycan fingerprints differing in relevant glycan traits correlating with their cellular phenotype as classified by the FAB system. By implementing transcriptomics data, specific glycosyltransferases and hematopoietic transcription factors were identified, which are candidate drivers of the glycan phenotype of these cells. In conclusion, we report the varying expression of glycan structures across a high number of AML cell lines, including those associated with poor prognosis, identified underlying glycosyltransferases and transcription factors, and provide insights into the regulation of the AML glycan repertoire.

show abstract

“…As the most extensively used anthracyclines, doxorubicin (Doxo) is currently approved to treat several neoplastic disorders including breast and gynecologic tumors, lymphoma, and lung cancer [5]. Moreover, Doxo-based chemotherapy also constitutes the standard care in osteosarcoma (OS), the most frequent primary bone-related tumor [6].…”

Section: Introductionmentioning

confidence: 99%

Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells

Salzillo

Ragone

Spina

et al. 2021

IJMS

View full text Add to dashboard Cite

Despite the recurring outbreak of resistance mechanisms and adverse reactions, doxorubicin (Doxo) still remains the standard-of-care for several cancers, including osteosarcoma (OS). As an appealing source of phytochemical compounds, naturally occurring molecules have extensively been reported to overcome Doxo limitations in preclinical models. Unlike other dietary polyphenols, only few studies recognize chlorogenic acid (CGA) as a potential partner in combination therapy, while, conversely, its anticancer evidence is steadily growing, ultimately in OS. On this basis, herein we examine the cooperating effects between CGA and Doxo in U2OS and MG-63 human OS cells. With respect to Doxo alone, the concomitant administration of CGA further decreased cell viability and growth, promoting cell death potentially via apoptosis induction. Furthermore, a longer-lasting reduction in clonogenic potential deeply supported the CGA ability to improve Doxo efficacy in those cells. Remarkably, CGA treatment ameliorated Doxo-induced cytotoxicity in H9c2 rat cardiomyocyte cells instead. Although inactivation of p44/42 MAPK was detected in response to CGA plus Doxo, PD98059-mediated p44/42 MAPK impairment enhanced the combination outcome in OS cells. These findings firstly propose CGA as a promising chemosensitizer and cardioprotective agent in OS therapy, suggesting the p44/42 MAPK pathway as relevantly involved in CGA-mediated Doxo susceptibility.

show abstract

A comprehensive review on time-tested anticancer drug doxorubicin

Cited by 242 publications

References 112 publications

Anticancer Activity of Propolis and Its Compounds

Anticancer Activity of Propolis and Its Compounds

Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines

Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells

Contact Info

Product

Resources

About